Skip to content

Evaluation of Early Retinal Nerve Injury in Type 2 Diabetes Patients Without Diabetic Retinopathy

Evaluation of Early Retinal Nerve Injury in Type 2 Diabetes Patients Without Diabetic Retinopathy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03970161
Enrollment
720
Registered
2019-05-31
Start date
2019-05-29
Completion date
2021-06-01
Last updated
2019-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Diabetic Retinopathy, Nerve Injury

Brief summary

The object of this study is to investigate the damage to the retinal nerve fiber layer (RNFL) and ganglion cell complex layer (GCL+) in diabetic patients without retinal microangioma as detected by fundus fluorescein angiography (FFA) and to determine the kind of nerve damage more likely to indicate early injury.

Detailed description

Patients with type 2 diabetes mellitus and healthy volunteers will be included in our study. Patients with retinal microangioma are excluded by FFA. The parameters around the optic disc and macular area of the above two groups are measured by optical coherence tomography (OCT), and the results will be analyzed using the SPSS 22.0 software.

Interventions

DEVICEroutine ophthalmic examination

Routine ophthalmic examination, including slit lamp, intraocular pressure, and fundus examinations using direct or indirect ophthalmoscopy after pupil dilation and optical coherence tomography (OCT) examination. Patients with DM also underwent fundus fluorescein angiography (FFA) examination.

Sponsors

Third Affiliated Hospital, Sun Yat-Sen University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

1. Patients with T2DM 2. Patients without microangioma

Exclusion criteria

1. Patients with any other ocular disease that might affect retinal nerve injury 2. Patients with optic neuropathy, age-related macular degeneration, retinal and choroidal disease, and retinal artery/vein occlusion. 3. Patients with hypertension, hematopathy, neuropathy, and other systemic diseases causing retinal nerve changes. 4. Patients with keratopathy, cataract, and vitreous hemorrhage were also excluded.

Design outcomes

Primary

MeasureTime frameDescription
Peripapillary RNFL thickness96 weeksPeripapillary RNFL thickness
GCL+ in the macular area obtained using the 3D wide mode96 weeksGCL+ in the macular area obtained using the 3D wide mode
Retinal thickness in all macular regions96 weeksRetinal thickness in all macular regions
RNFL thickness in the macular area obtained using the 3D Macula (v) mode96 weeksRNFL thickness in the macular area obtained using the 3D Macula (v) mode
GCL+ thickness in the macular region obtained using the 3D Macula (v) mode96 weeksGCL+ thickness in the macular region obtained using the 3D Macula (v) mode

Countries

China

Contacts

Primary ContactXiang Zhu
0628zhuxiang@163.com13826452564

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026